POLA-R-CHP in the First-line Treatment of Transformed DLBCL

NCT06743945 | Recruiting Phase 2

• 1 other identifier: iNHL-05
• Study Type: interventional
• Target: 20
• Locations: 1 country
• Sites: 1

Brief Summary

This study aims to evaluate efficacy and safety of POLA-R-CHP in the treatment of patients with transformed DLBCL.

Conditions

Transformed Lymphoma

Outcome Measures

Primary Outcomes (1)

• 2-year progression-free survival (PFS) assessed by imaging examination

  the period from the date of patients sign informed consent to the observed progression of the disease or the occurrence of death for any reason

  From date of patients sign informed consent until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 2 years

Secondary Outcomes (4)

• complete remission rate assessed by imaging examination

  up to 6 months

• 2-year event-free survival (EFS)

  From date of patients sign informed consent until the date of first documented event, progression or date of death from any cause, whichever came first, assessed up to 2 years

• 2-year overall survival rate

  From date of patients sign informed consent until the date of death or the date of last follow-up time, whichever came first, assessed up to 2 years

• Number of participants with treatment-related adverse events as assessed by CTCAE v5.0

  Through study completion, up to 2 years

Other Outcomes (1)

• tissue biomarkers

  Throughout the treatment period, up to 2 years

Study Arms (1)

Experimental group

EXPERIMENTAL

POLA-R-CHP

Drug: POLA-R-CHP

Interventions

POLA-R-CHP DRUG

Pola-R-CHP is a combination of rituximab, cyclophosphamide, doxorubicin, prednisone, and polatuzumab vedotin

Also known as: polatuzumab vedotin and R-CHP

Experimental group

Eligibility Criteria

• Age: 18 Years - 80 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Age 18 -80 years old;
• Histologically confirmed transformed DLBCL;
• ECOG 0-2;
• Signed informed consent form.
• Having sufficient organ function: a) Hematopoietic function: Neutrophils ≥ 1.0 × 109/L, PLT ≥ 75 × 109/L, Hb ≥ 90g/L(unless caused by underlying disease, as judged by the investigator, such as extensive bone marrow involvement, or hypersplenism secondary to lymphoma splenic involvement); b) Liver function: bilirubin ≤1.5 times the upper limit of normal (ULN), ALT and AST\<3 x ULN, serum albumin ≥ 30 g/L; c) Renal function: serum Cr\<1.5 × ULN, creatinine clearance rate ≥ 50mL/min (calculated according to the standard Cockcroft Gault formula, if renal dysfunction is caused by tumor compression, creatinine clearance rate ≥ 30mL/min); d) Left ventricular ejection fraction (LVEF) ≥ 50% detected by echocardiography.

You may not qualify if:

• Individuals who are allergic to human or mouse monoclonal antibodies, or known sensitivity or allergic reaction to murine products;
• Previous organ transplantation;
• Prior treatment of any condition (e.g., cancer, rheumatoid arthritis) with cytotoxic drugs within 5 years at the time of screening or prior use of any anti-CD20 antibodies;
• Evidence of uncontrolled significant comorbidities that may affect the patient's compliance with the study protocol or affect the interpretation of the study results, including significant cardiovascular disease (such as New York College of Cardiology Class III or IV heart disease, myocardial infarction within the past 6 months, unstable arrhythmia, or unstable angina) or pulmonary disease (including history of obstructive pulmonary disease and bronchospasm);
• Recent major surgery (within 4 weeks prior to enrollment), excluding diagnostic surgery;
• Known active bacterial, viral, fungal, mycobacterial, parasitic or other infections (except for fungal infections in nail beds) at the time of study enrollment or major infections within 2 weeks before the start of the first course of treatment;
• Previous radiotherapy in the mediastinum/pericardial region;
• Active chronic hepatitis B infection (defined as HBV DNA positive): If hepatitis B virus (HBV) DNA cannot be detected during screening, patients with latent or previous hepatitis B infection (defined as positive hepatitis B surface antigen or hepatitis B core total antibody) can be included in this study. The above patients must voluntarily undergo regular HBV-DNA testing and receive appropriate antiviral treatment according to regulations.
• For patients with positive hepatitis C virus (HCV) antibody serological test, only when polymerase chain reaction (PCR) shows negative HCV-RNA can participate in this study.
• Patients with active HIV and syphilis infections;
• Pregnant or lactating women;
• The researcher determined that patients are not suitable to participate in this study.

Sponsors & Collaborators

• Fudan University: lead

Study Sites (1)

Fudan University Shanghai Cancer Center

Shanghai, Shanghai Municipality, 200032, China

RECRUITING

MeSH Terms

Interventions

polatuzumab vedotin

Study Officials

• Yizhen Liu, M.D., Ph.D.

  Fudan University

  PRINCIPAL INVESTIGATOR

Central Study Contacts

Yizhen Liu, M.D., Ph.D.

CONTACT

021-64175590; aliuyz@126.com

Study Design

• Study Type: interventional
• Phase: phase 2
• Allocation: NA
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: SINGLE GROUP
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Clinical Professor

Study Record Dates

• First Submitted: December 15, 2024
• First Posted: December 20, 2024
• Study Start: February 17, 2025
• Primary Completion (Estimated): December 1, 2027
• Study Completion (Estimated): December 1, 2029
• Last Updated: February 25, 2025

Record last verified: 2025-02

Data Sharing

• IPD Sharing: Will not share

Locations

CN (1)